MX2017009110A - Terapia de combinacion para hipertension pulmonar. - Google Patents
Terapia de combinacion para hipertension pulmonar.Info
- Publication number
- MX2017009110A MX2017009110A MX2017009110A MX2017009110A MX2017009110A MX 2017009110 A MX2017009110 A MX 2017009110A MX 2017009110 A MX2017009110 A MX 2017009110A MX 2017009110 A MX2017009110 A MX 2017009110A MX 2017009110 A MX2017009110 A MX 2017009110A
- Authority
- MX
- Mexico
- Prior art keywords
- pulmonary hypertension
- combination therapy
- bmpr2
- treatment
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona composiciones y métodos para el tratamiento de hipertensión pulmonar utilizando la terapia de combinación. La terapia de combinación comprende un compuesto que incrementa la señalización de BMPR2 (activador de BMPR2) en combinación con por lo menos otro agente para el tratamiento de hipertensión pulmonar. En ciertos aspectos, el activador de BMPR2 puede ser tacrolimus o un solvato o sal o profármaco farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562103020P | 2015-01-13 | 2015-01-13 | |
PCT/US2016/012694 WO2016114993A1 (en) | 2015-01-13 | 2016-01-08 | Combination therapy for pulmonary hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017009110A true MX2017009110A (es) | 2017-11-09 |
Family
ID=56406244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017009110A MX2017009110A (es) | 2015-01-13 | 2016-01-08 | Terapia de combinacion para hipertension pulmonar. |
Country Status (12)
Country | Link |
---|---|
US (3) | US20180325875A1 (es) |
EP (1) | EP3244968B1 (es) |
JP (1) | JP6890540B2 (es) |
KR (1) | KR102569428B1 (es) |
CN (1) | CN107427698A (es) |
AU (1) | AU2016207046B2 (es) |
BR (1) | BR112017014914B1 (es) |
CA (1) | CA2973114C (es) |
IL (1) | IL253325A0 (es) |
MX (1) | MX2017009110A (es) |
NZ (1) | NZ733451A (es) |
WO (1) | WO2016114993A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
EP3554507A1 (en) | 2016-12-14 | 2019-10-23 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
CN112569357B (zh) * | 2019-09-30 | 2023-03-28 | 深圳奥萨制药有限公司 | 双重内皮素受体拮抗剂与利尿剂的组合物 |
IL293271A (en) * | 2019-11-29 | 2022-07-01 | Actelion Pharmaceuticals Ltd | Methods for treating pulmonary artery hypertension |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110171193A1 (en) * | 2008-06-12 | 2011-07-14 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating pulmonary hypertension |
PT2704711T (pt) * | 2011-05-02 | 2021-03-02 | Univ Leland Stanford Junior | Utilização de fk506 para o tratamento da hipertensão arterial pulmonar |
AU2012252165A1 (en) | 2011-05-09 | 2013-03-21 | Cambridge Enterprise Limited | Methods of modulating micrornas in the treatment of pulmonary arterial hypertension |
EP2827849A4 (en) * | 2012-03-23 | 2015-11-18 | Univ Leland Stanford Junior | TREATMENT OF PULMONARY HYPERTONIA WITH LEUKOTRIENHEMMERN |
-
2016
- 2016-01-08 MX MX2017009110A patent/MX2017009110A/es unknown
- 2016-01-08 WO PCT/US2016/012694 patent/WO2016114993A1/en active Application Filing
- 2016-01-08 BR BR112017014914-1A patent/BR112017014914B1/pt active IP Right Grant
- 2016-01-08 KR KR1020177022273A patent/KR102569428B1/ko active IP Right Grant
- 2016-01-08 CN CN201680015289.1A patent/CN107427698A/zh active Pending
- 2016-01-08 US US15/543,510 patent/US20180325875A1/en not_active Abandoned
- 2016-01-08 AU AU2016207046A patent/AU2016207046B2/en active Active
- 2016-01-08 CA CA2973114A patent/CA2973114C/en active Active
- 2016-01-08 EP EP16737651.6A patent/EP3244968B1/en active Active
- 2016-01-08 NZ NZ733451A patent/NZ733451A/en unknown
- 2016-01-08 JP JP2017536934A patent/JP6890540B2/ja active Active
-
2017
- 2017-07-05 IL IL253325A patent/IL253325A0/en unknown
-
2019
- 2019-04-11 US US16/381,128 patent/US20200069658A1/en not_active Abandoned
-
2021
- 2021-05-11 US US17/317,274 patent/US20210267951A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112017014914A2 (pt) | 2018-03-13 |
BR112017014914B1 (pt) | 2023-11-14 |
AU2016207046B2 (en) | 2021-04-01 |
JP6890540B2 (ja) | 2021-06-18 |
KR20170103918A (ko) | 2017-09-13 |
US20180325875A1 (en) | 2018-11-15 |
EP3244968B1 (en) | 2023-08-30 |
IL253325A0 (en) | 2017-09-28 |
US20200069658A1 (en) | 2020-03-05 |
CA2973114C (en) | 2023-04-04 |
NZ733451A (en) | 2023-02-24 |
CN107427698A (zh) | 2017-12-01 |
KR102569428B1 (ko) | 2023-08-21 |
EP3244968A4 (en) | 2018-09-12 |
JP2018502126A (ja) | 2018-01-25 |
WO2016114993A1 (en) | 2016-07-21 |
RU2017128481A3 (es) | 2019-06-25 |
EP3244968A1 (en) | 2017-11-22 |
RU2017128481A (ru) | 2019-02-14 |
US20210267951A1 (en) | 2021-09-02 |
CA2973114A1 (en) | 2016-07-21 |
AU2016207046A1 (en) | 2017-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
NZ737004A (en) | Triazole agonists of the apj receptor | |
WO2015153514A8 (en) | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists | |
MX2021007773A (es) | Compuestos inhibidores de egfr. | |
SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
PH12016500270A1 (en) | Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases | |
MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
PH12017500881B1 (en) | Aurora a kinase inhibitor | |
PH12016501751A1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
NZ733451A (en) | Combination therapy for pulmonary hypertension | |
MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. | |
WO2015181624A3 (en) | Nucleoside derivatives for the treatment of cancer | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
MX2017014436A (es) | Compuestos biciclicos. | |
MX2017007000A (es) | Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas. | |
WO2015175884A3 (en) | Compositions and methods for treating and preventing pancreatitis, renal injury and cancer | |
MX2019009200A (es) | Composiciones y métodos para inhibir el reticulón 4. | |
MX2017014301A (es) | Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar. | |
MX2017013453A (es) | Uso de (4-hidroxi-2-metil-1,1-dioxido-2h-benzo [e] [1, 2] tiazin-3-il) (naftalen-2-il) metanona en la prevencion y/o tratamiento de esteatohepatitis no alcoholica. |